Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 8/20 | 0.45 |
| ▸ | PIM1 | P11309 | 2/20 | 0.42 |
| ▸ | CDC7 | O00311 | 3/20 | 0.40 |
| ▸ | GCGR | P47871 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 2/20 | 0.37 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3339626 | 0.84 | XDH (0.44) | XDHPIM1CDC7GCGRMAPK14 | |
| SCHEMBL14023022 | 0.81 | PIM1 (0.55) | XDHPIM1CDC7GCGRMAPK14 | |
| SCHEMBL386224 | 0.79 | PIM1 (0.67) | XDHPIM1CDC7GCGRMAPK14 | |
| SCHEMBL3342615 | 0.78 | TP53 (0.43) | XDHPIM1GCGRMAPK14KDM4E | |
| SCHEMBL3342410 | 0.76 | CDC7 (0.41) | XDHPIM1CDC7GCGRMAPK14 | |
| SCHEMBL14023056 | 0.76 | PIM1 (0.41) | XDHPIM1CDC7GCGRMAPK14 | |
| SCHEMBL3341849 | 0.75 | CDC7 (0.40) | XDHPIM1CDC7GCGRMAPK14 | |
| SCHEMBL3340593 | 0.75 | XDH (0.52) | XDHPIM1CDC7 | |
| SCHEMBL3340787 | 0.74 | PDE5A (0.40) | PIM1GCGRMAPK14PDE5APDE4A | |
| SCHEMBL3338542 | 0.74 | KDM4E (0.41) | XDHPIM1CDC7GCGRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074114-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2013-03-06 | — | — | EP | claimed |
| US-8324231-B2 | Pyrimidinones as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-12-04 | — | — | US | claimed |
| US-20100144770-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. (US) | 2010-06-10 | — | — | US | claimed |
| EP-2074114-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8324231-B2 | Pyrimidinones as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324231-B2 | Pyrimidinones as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324231-B2 | Pyrimidinones as casein kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100144770-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144770-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144770-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2074114-A1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008143759-A1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144770-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | CSNK2A1, CSNK2A2, CSNK1A1 | XDH 283/4885PIM1 579/4885CDC7 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.